This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Azathioprine in multiple sclerosis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Azathioptine therapy in multiple sclerosis:

  • azathioprine therapy in multiple sclerosis may have similar efficacy to beta-interferon but initial trial evidence seemed less conclusive (1,2)

  • however a meta-analysis concluded that azathioprine probably does attenuate relapsing remitting MS (3)

Reference:

  • 1) Yudkin PL, Ellison GW, Ghezzi A, Goodkin DE, Hughes RA, McPherson K, Mertin J, Milanese C. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991 Oct 26;338(8774):1051-5
  • 2) Palace J, Rothwell P. New treatments and azathioprine in multiple sclerosis.Lancet 1997 Jul 26;350(9073):261.
  • 3) Casetta I, Iuliano G, Filippini G. Azathioprine for multiple sclerosis. Cochrane Database Syst Rev 2007:CD003982.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.